ResearcherShowa Pharmaceutical UniversityActive in the last 2 years
Yoshihito Morimoto
Matched on ORCID iD 0000-0002-1058-0614; OpenAlex author ID A5058253503. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 5
- Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer. Co-author DOI 10.1007/s12672-026-05581-1↗
- Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells. Co-author DOI 10.1007/s00280-024-04716-x↗
- Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition … Co-author DOI 10.1007/s11010-020-03796-6↗
- Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1. Co-author DOI 10.3892/or.2019.7421↗
- Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Co-author DOI 10.1097/cad.0b013e328350e8c7↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yutaka Masuda · 4 shared papers, 2020–2026 · strength 0.82
- Paper Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer. DOI 10.1007/s12672-026-05581-1↗
- Paper Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells. DOI 10.1007/s00280-024-04716-x↗
- Paper Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in… DOI 10.1007/s11010-020-03796-6↗
- Yoshinori Yamada · 1 shared paper, 2012 · strength 0.03
- Yukio Suzuki · 1 shared paper, 2012 · strength 0.03
- Hiroshi Yoneyama C · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.